Brain gene therapy hopes to restore dopamine in young Parkinson's patients
Disease control
Not yet recruiting
This early-stage study tests a gene therapy called AAV2-hAADC in 9 adults aged 18-75 with young onset Parkinson's (symptoms before age 50). The therapy delivers a gene into brain areas that help turn levodopa into dopamine, the chemical missing in Parkinson's. The main goal is to…
Phase: PHASE1 • Sponsor: Krzysztof Bankiewicz • Aim: Disease control
Last updated May 22, 2026 13:53 UTC